Peterson Jared D, Bedrossian Edward H
Oculoplastic and Orbital Surgery Service, Wills Eye Institute, Philadelphia, PA 19107, USA.
Orbit. 2012 Apr;31(2):119-23. doi: 10.3109/01676830.2011.648818.
Bisphosphonates are becoming more widespread as indications for them broaden. Several ocular side effects due to bisphosphonates have been described, among the most potentially serious of which is orbital inflammation. Thirteen case reports of this side effect exist in the literature, with an additional case reported here. The most common presenting signs are lid edema, conjunctival hyperemia, and chemosis, while common symptomatology includes pain, diplopia, and blurry vision. A concomitant anterior uveitis is present in 30% of cases, and some degree of bilaterality is also seen in 30% of cases. There are two reported instances of profound visual loss, highlighting the importance of prompt recognition and treatment of this entity. Despite a paucity of rechallenge data, available reports suggest that development of orbital inflammation does not necessarily exclude patients from future bisphosphonate use.
随着双膦酸盐类药物的适应证不断拓宽，其使用越来越广泛。双膦酸盐类药物已被描述有多种眼部副作用，其中最具潜在严重性的是眼眶炎症。文献中有13例关于这种副作用的病例报告，本文再报告1例。最常见的表现体征是眼睑水肿、结膜充血和球结膜水肿，常见症状包括疼痛、复视和视力模糊。30%的病例伴有前葡萄膜炎，30%的病例也有一定程度的双侧性。有2例报告出现严重视力丧失，凸显了及时识别和治疗该病症的重要性。尽管再次用药的数据较少，但现有报告表明，眼眶炎症的发生不一定会使患者未来不能使用双膦酸盐类药物。
